Spectrum of COL4A5 mutations in large AS
sensorineural hearing loss, ocular lesions, and typical changes of the glomerular basement membrane population screenings (GBM ) . Interestingly, AS shows a wide range of phenotypic expression, including purely renal forms, Recent studies from large AS populations (more than as well as extrarenal features such as hearing loss, 640 patients extensively screened) have described over ocular and haematological findings, and diÂuse smooth 140 small mutations in the COL4A5 gene (Table 2 ) muscle cell benign tumours (see below). AS can be [2] [3] [4] [5] . The mutations are spread all over the gene, with further associated with juvenile (<31 years) or adult no evidence of mutational hot spots. All types of onset (>31 years) of end-stage renal disease (ESRD). changes were detected, including missense, frameshifts, The variability of the clinical phenotype can be par-nonsense, small deletions and insertions, and splicing tially explained by genetic and molecular heterogeneity. mutations. Importantly, even in selected subpopula-AS is in fact caused by mutations in any of several tions of patients with clear AS diagnosis and X-linked genes encoding various type IV collagen chains. This inheritance pattern, the mutation detection rate was is referred to as locus heterogeneity, i.e. mutations in less than 50%. Several reasons might account for this more than one gene causing similar or indistinguishable discrepancy: low sensitivity of the screening methods, phenotypes. The culprit AS genes are COL4A3 and COL4A4 on chromosome 2q35-37, and COL4A5 on review on AS see reference [1 ] ).
Autosomal dominant AS COL4A3 or A4 (?) Autosomal dominant BFHa COL4A3 or A4
aBenign familial haematuria.
Molecular basis for AS classification
Before the availability of molecular genetic diagnosis, Table 2 . COL4A5 mutation screening results obtained in some recent large AS population surveys the classification of AS was based mainly on clinical parameters. Now, based on molecular genetic parameters, AS can be classified in at least four diÂerent AS patients Mutations COL4A5 exons Reference studied (n) identified (n) screened (n) nosological entities, and if we also take into account familial benign haematuria ( FBH ), the 'AS phenotype' and mutations in non-coding areas, such as introns or Genotype/phenotype correlations regulatory regions; mutations within the adjacent COL4A6 gene appear not likely to cause disease [3] . One of the most relevant clinical benefits of molecular Finally, no particular phenotypic features distinguished studies is the significant correlation between the age of the families where mutations were found from the onset of ESRD in AS and the nature of the underlying other families. COL4A5 mutation. In fact, mutations predicted to lead to truncated or absent alpha 5 (IV ) chain, such as severe inactivating (null ) mutations (frameshifts,
Autosomally inherited AS and benign familial
nonsense, and large rearrangements), consistently
haematuria (BFH)
cause juvenile-type disease, usually with deafness. The lack of the C-terminal NC (non-collagenous) domain The rarer autosomal recessive AS phenotype has been of the molecule might prevent the critical step of triple demonstrated by the identification of pathogenic muta-helical formation, with dramatic alterations of the tions in COL4A3 and COL4A4 genes [6 ] . Typically, protein and thus severe derangement of the GBM these families lack a positive history, females appear structures. Conversely, amino acid substitutions (missas severely aÂected as males, and the asymptomatic sense changes) can lead to either juvenile or adultparents are often consanguineous. Patients normally onset AS, and virtually all adult cases bear either reach ESRD before the age of 30. The correct molecu-splice-site mutations or missense changes involving lar identification of this type of families can bear glycine substitutions, which aÂect the proper folding crucial implications for genetic counselling [7] .
of the molecule. Nonetheless, these mutations might Autosomal dominant AS has been sporadically allow some type IV collagen processing and assembly. reported, often in association with haematological ( platelet and granulocyte) alterations. Recently this
Conclusions and future perspectives
very rare form was also linked to the COL4A3/A4 region on chromosome 2q35-37, but no mutations have been found (JeÂerson et al., abstract, Third Why can such diverse clinical phenotypes in AS arise from diÂerent mutations in the same gene? Explaining International Workshop on Alport Syndrome, Erlangen, Germany, September 1994).
the underlying mechanism(s) of this phenomenon, which has also been referred to as 'phenotypic diversity BFH is an autosomal dominant condition characterized by GBM thinning and normal renal function, from allelic series' [11 ], is not easy. One reason could be the diÂerent functional domains involved by the sometimes diÃcult to diÂerentiate from the initial stages of AS. Interestingly, BFH has been recently mutations, causing diÂerent consequences. Other factors might involve interactions of additional mutations linked to a mutation in the COL4A4 gene [8 ] and possibly COL4A3 [9 ] , raising the attractive suggestion and/or 'benign' polymorphisms in the same gene, with modification of clinical expression. A family with very that BFH patients might be manifesting heterozygous carriers of autosomal recessive AS. However, further severe AS has been described bearing two missense mutations on the same COL4A5 allele [4 ] . Finally, studies are needed to unravel the molecular mechanisms by which the BFH phenotype does not progress interactions among mutations in diÂerent, 'modifier' genes, commonly referred to as our 'genetic backtowards ESRD. It's also tempting to speculate that the severe autosomal recessive AS and the milder BFH ground', might also cause phenotypic diversity. This in turn could explain the common phenomena of phenotypes represent two extremes, due to diÂerent 'dosages' of COL4A3/A4 mutations, homozygous and incomplete penetrance and variable expression, so puzzling to geneticists. . In AS, At least 35 cases have been now described of AS associated with diÂuse oesophageal leiomyomatosis, a however, the phenotypic variability appears mainly quantitative, reminiscent of the wide spectrum of disphenotype also belonging to the AS spectrum (see [1] ). Both COL4A5 and COL4A6, which lie just 450 bp ease in CFTR mutation carriers, associated with diÂerent levels of mRNA transcript [12 ] . apart in a head-to-head fashion, are aÂected, usually by large deletions removing the 5∞ ends of the two The 'phenotype' results from complex ontogenic and developmentally regulated steps, where genes and nongenes. These findings indicate still unknown but important role (s) of the two genes in the normal genetic factors interact. In this scenario the genotype appears as a necessary but not suÃcient component. processes of morphogenesis, diÂerentiation and proliferation in smooth-muscle cells. The proliferative Thus, even 'simple' monogenic traits should be considered multifactorially determined, and the genotype/ changes are probably induced by aberrant and inappropriate alpha 6 (IV ) chain synthesis triggered by an phenotype relationship expected to be irregular and variable. alternative distal promoter, spared by the deletion [10] . providing a 'molecular prognosis' to our AS patients, 6 . Mochizuki T, Lemmink HH, Mariyama M et al. Identification we might be able to predict early or late onset disease, of mutations in the alpha 3 ( IV ) and alpha 4 ( IV) collagen whether or not a severe inactivating mutation is found. today the elderly tend to be, on average, more healthy interlobular arteries and increased tortuosity of intralobular arteries [7 ] . The pattern of glomerular and than in the past.
Because of the important eÂect of confounding vascular changes diÂers according to renal zones: whereas in the cortex hyalinization and collapse of the variables it is of note that only one longitudinal study has been published that extended over more than 20 glomerular tufts goes in parallel with obliteration of preglomerular arterioles, anatomical shunts between years. Despite the use of serial measurements of creatinine clearance as a less than ideal marker of GFR, the aÂerent and eÂerent arterioles are commonly seen in the juxtamedullary region [7] . If one evaluates studies 'Baltimore Longitudinal Study on Aging' is a milestone insofar as it revealed two important facts: (i) in no examining age-related changes in renal structure it is again important to exclude the elderly with disease. less than one-third of apparently healthy elderly subjects there was no decrease of GFR at all, and (ii) a This includes not only the elderly with hypertension, but also the elderly with atherosclerosis of the abdomdecrease in GFR was found to be associated primarely with cardiovascular diseases (e.g. hypertension, inal aorta [8 ] . In the past elevated mean arterial blood pressure has been recognized as one factor aÂecting oedema of unknown origin) [1 ] . Recent studies showed that in the healthy elderly GFR (by inulin clearance) renal function. It may be equally important to take into consideration diminished aortic elasticity, which is mostly within the normal range, although lower than in younger individuals [2, 3] . An exception is the elderly causes an increase in pulse pressure with important consequences for the pulse profile and the mechanical with consuming diseases and heart failure. In elderly patients with mild compensated heart failure (NYHA stress to which peripheral vessels are exposed. More careful exclusion of patients with comorbid conditions I-II ) GFR is significantly lower than in normotensive healthy elderly subjects [3] . We conclude that in the may explain, at least in part, why more recent postmortem (and imaging ) studies find a less severe elderly a major decrease of GFR is uncommon in the absence of disease. Apparently, the population of decrease in renal size and less glomerulosclerosis with ageing than did studies in the past [8, 9] . elderly is heterogenous. It is of considerable interest that centenarians are, on average, more healthy than the average octagenarian [4 ] . This observation is compatible with the view that a subgroup of healthy elderly Missing information stay alive, while the more frail ones die oÂ (healthy survivor eÂect). This underlines again how important Consideration of the above methodological points will it is to take care in selecting subjects for studies.
help in the future to ask more intelligent questions and How about more subtle indices of renal function? to analyse the data in a more sophisticated fashion. EÂective renal plasma flow is reduced proportionally In-depth analysis of the eÂect of ageing is hampered more than GFR and vasodilatation in response to by the fact that the general mechanisms of ageing are agonists such as acetylcholine or amino acids is dimin-poorly understood. Accumulation of mutations in ished [2, 5] . As a consequence, even in the healthy somatic DNA, particularly in mitochondrial DNA, elderly, filtration fraction ( FF ) is increased [3 ] . The irreversible commitment of stem cells to terminally kidney is vasoconstricted similarly to what also occurs diÂerentiated cells, accumulation of oxidative damage in extrarenal vascular beds. These subtle age-related and advanced glycosylation end-products have all been abnormalities of renal haemodynamics are more proposed as playing a role in ageing [4] . None of the marked in patients with cardiovascular disease. They proposed mechanisms has so far provided a satisfactare accompanied by, or predispose to, changes in renal ory explanation for age-related changes in renal funcelectrolyte handling and hormonal status, i.e. increased tion. proximal tubular sodium reabsorption, decreased plasma renin activity, low calcitriol, and elevated parathyroid hormone concentration [3] .
What are the clinical consequences?
Better understanding of the eÂects of ageing of the Renal structure kidney may have implications for (i) use of kidney from elderly donors for organ donation, (ii) pharmacokinetics of drugs cleared by the kidney, and (iii) It is well known that ageing is associated with some loss of renal mass, but not all renal structures are understanding of the age-specific prevalence of diÂer-ent renal disease in the elderly. The incidence of renal aÂected in a similar fashion. Involution of renal tissue and glomerulosclerosis occurs primarily in the renal failure from various renal diseases increases proportionaly with age. This may be due to one or more of cortex with relative sparing of the renal medulla [5, 6] . Selective loss of cortical and preservation of juxtamed-the following factors: (i) a higher prevalence of the conditions leading to renal disease in the elderly, ullary nephrons with higher FF may explain, at least in part, the rise in FF with age. Not only does one see particularly hypertension, type 2 diabetes mellitus, atherosclerosis, and vasculitis, (ii) increased susceptisclerosis of glomeruli, but also sclerosis of larger renal vessels. In addition, a high prevalence of abnormalities bility of the kidney of the elderly to the renal complications of the above diseases, and (iii) accelerated was reported in the renal vasculature, e.g. tapering of Introduction-disease susceptibility in Indo-Asians compared to a White diabetic. This seen as a greater prevalence of proteinuria among Indo-Asians in a There are large Indo-Asian communities in several diabetic clinic, a susceptibility independent of glycacities in the United Kingdom. In Leicester for example emic control or hypertension [1 ] . But in Leicester the there are 60 000 Indo-Asians, 20% of the population risk of an Indo-Asian diabetic developing ESRD is of the city. They originate from the Indian subcontinent also increased to more than 10 times that of a White and the term Indo-Asian is preferred to avoid confusion diabetic [2] . This very powerful eÂect appears to reflect with many studies of Asians from North America susceptibility rather than risk of progression once which usually refer to populations originating mainly diabetic nephropathy has occurred-neither rates of from Japan and South East Asia. Patterns of disease progression nor control of blood pressure diÂer in Indo-Asians contrast markedly with those in indibetween Indo-Asian and White diabetics. genous White populations; in particular Indo-Asians
The Indo-Asian susceptibility to renal disease is not have a strikingly increased prevalence of coronary restricted to diabetic nephropathy. Indo-Asians have heart disease, type II diabetes, and renal disease, as an increased incidence of immune renal disease, which well as susceptibility to tuberculosis [1 ] . The type II may not progress to renal failure-steroid sensitive diabetes has a relatively young age of onset and nephrotic syndrome in children and lupus nephritis prevalence increases with age: 30% of the Indo-Asian population aged greater than 60 years are diabetic.
[1]. ESRD due to non-diabetic renal disease is also The population at risk for the development of ESRD three to five times as common in Indo-Asians; this due to diabetic nephropathy is therefore increased in includes ESRD due to biopsy-proven glomeruloan Indo-Asian community. But the Indo-Asian diabetic nephritis, chronic pyelonephritis and renal failure of uncertain cause presenting with shrunken kidneys [3 ] . It has been suggested that tuberculosis may play a role
Correspondence and oÂprint requests to: Dr John Feehally, in the renal failure of undetermined cause, but this is Department of Nephrology, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK.
unproven [3] .
Other high-risk populations Environmental and in utero environmental factors
In migrant populations all over the world, including Are there comparable populations elsewhere in the Indo-Asians, there has been an 'epidemic' of type II world? African Americans have an excess of type II diabetes, which may be explained in part by environdiabetes but also have severe hypertension, which is mental influences-the consumption of an energy-rich not seen in Indo-Asians. Similar increases in diabetes processed 'western' diet combined with a reduction in and renal failure are also seen in Polynesian populaphysical exercise. Neel [6 ] proposed a 'thrifty genotype' tions in Australasia. The closely studied Pima Indians (rapid insulin release promoting fat storage and in Arizona, USA have the world's highest incidence of reduced calorie wastage), which would confer survival type II diabetes. The vast majority of ESRD in the advantage during times of fasting but during prolonged Pimas occurs in diabetics, and of that virtually all is feasting (urbanization) would confer risk of insulin attributable to diabetic nephropathy [4 ] . In contrast, resistance, central obesity, and diabetes. Barker et al. another group of American Indians, the Zunis of New [7] has suggested that maternal undernutrition during Mexico, carry a very high risk of ESRD due to pregnancy results in an increased susceptibility to type glomerulonephritis, with little diabetic nephropathy II diabetes; thus the 'thrifty genotype' should be [5] .
renamed the 'thrifty phenotype' and syndrome X be called the 'small-baby syndrome'. He proposed that
The Indo-Asian paradigm the fetus is 'programmed' in utero by irreversible changes in response to the fetal environment. Mackenzie and Brenner [8 ] have combined the concept The Indo-Asian therefore carries risks seen in both the of 'programming' with that of 'nephron dose' sugPimas and the Zunis, and has a most unfortunate gesting that nephron number at birth may be the 'double jeopardy'-susceptibility to type II diabetes missing link between birthweight and hypertension. and to renal disease. This unhappy coincidence proContinuing organogenesis of the kidney into the third vides a challenge for health care provision for ESRD trimester, with induction of some 60% of the normal in areas with large Indo-Asian communities; but also complement of nephrons during this period, could an opportunity to pursue mechanisms of renal disease. make the kidney uniquely susceptible to maternal Indo-Asians have come to Britain either directly malnutrition, which would reduce nephron number. from the Indian subcontinent, or via stable migrant There is emerging evidence that fetal kidney growth is communities in sub-Saharan Africa. This migration disproportionately restricted in the small-foroccurred very rapidly over 20 years from the late gestational-age fetus [9 ] and evidence that in women 1960s. This rapid move of a large population in a short the risk of diabetic nephropathy is doubled between time oÂers an unrivalled opportunity to compare the those with lowest and highest birthweights, although pathogenic influence of genetic and environmental no such relationship in men was found [10 ] . factors, including the prenatal environment at which As yet assessment of birthweight and subsequent time it is thought that individual susceptibility to risk has not yet been undertaken in Indo-Asians. disease later in life may be 'programmed' Nevertheless low birthweight would be an attractive explanation for the increased prevalence of type II diabetes, and might also explain, because of reduced Genetic factors nephron dose, the increased incidence of all forms of renal disease in Indo-Asians. (However, Mackenzie Familial clustering of nephropathy is well described in and Brenner's hypotheses do not fit the Indo-Asian type I diabetes. There is some evidence that this population in their entirety, since there is susceptibility susceptibility is inherited as a familial predisposition to renal disease and diabetes without hypertension and to hypertension marked by increased velocity of the renal failure is so common despite a vegetarian lowred-cell sodium-lithium countertransport system. protein diet.) However no role for abnormalities in this system have The great majority of Indo-Asians in Britain who been found in type II diabetes. Nor is there any proven are now developing ESRD due to diabetic nephropathy influence of ACE gene polymorphisms in type II were born in India or Africa, and reliable birthweight diabetes despite some evidence that this polymorphism data are not available. However, birthweights among may be linked to risk of progression of renal failure in Indo-Asians in Leicester are lower than in the equivaother disease groups. Nevertheless there is familial lent White population, although any influence of chansusceptibility to nephropathy in African Americans ging birthweight on the prevalence of type II diabetes with type II diabetes and in Pima Indians there is also and renal failure will take some generations to be clustering in families. Our own observations suggest a detected with certainty. similar familial susceptibility to nephropathy in IndoAsian diabetics but this has not been formally studied.
Conclusion
There have been no studies of the sodium-lithium countertransporter nor of ACE gene polymorphisms in Indo-Asians; but studies of these and other candidate The geopolitics which resulted in the Indo-Asian migration to Leicester may aÂord a unique opportunity to genes may soon prove informative. Cardiovascular complications remain the leading cause rise of blood pressure in the first hours after dialysis. This could explain the discrepancy between the findings of death in haemodialysis ( HD) patients [1] .
of Cheigh et al. [4] , who observed a return to preHypertension predisposes to structural abnormalities dialytic values within 12 hours after rapid and short of the cardiovascular system and is identified as an ultrafiltration and the results of Battistella et al.
[5] important risk factor for cardiovascular disease in this and our group [6 ] , in which blood pressure values population [1, 2] . Therefore, adequate diagnosis and gradually returned to pre-dialytic values during the treatment of hypertension in HD patients is a logical inter-dialytic period. In the latter studies, post-dialytic step in the prevention of cardiovascular morbidity and values appeared to be more representative for intermortality in this population.
dialytic values [5, 6 ] . Therefore, the sole use of predialytic values may lead to overestimation of the incidence of hypertension, whereas post-dialytic blood Definition of hypertension in HD patients: Which is pressure may lead to an underestimation of intradiathe biologically most relevant blood pressure value?
lytic blood pressure because of intravascular underfillSome problems arise with the diagnosis and definition ing. In doubtful cases, inter-dialytic ambulatory blood of hypertension in HD patients. Pre-dialytic values pressure measurements may be helpful. Ambulatory may overestimate inter-dialytic blood pressure because blood pressure measurements also informs us about of factors such as volume overload or the accumulation the day-night blood pressure rhythm, which is often of vasoactive factors in the inter-dialytic period (to be disturbed in uraemic patients [6 ] . In patients with discussed later), whereas post-dialytic blood pressure essential hypertension, it was found that ambulatory may be influenced by the dialysis procedure itself. The blood pressure measurements correlated better with fact that refill of plasma volume from the interstitial end-organ damage compared with oÃce blood pressure volume is not yet completed after dialysis, a phenom- [7] . If this also holds true for dialysis patients remains enon that is most pronounced after short and rapid to be elucidated. ultrafiltration [3] , and at underhydration, may lead to an understimation of inter-dialytic blood pressure by What is the role of volume overload?
post-dialytic values. In consequence, intravascular underfilling during dialysis may be followed by a rapid Undoubtably, a major role in the pathogenesis of hypertension in HD patients is played by fluid retention, as the majority of HD patients become normot- 
of endogenous inhibitors of nitric oxide, like asymmetvolume status and blood pressure levels [8, 9] . Moreover, a significant proportion ( 15-25%) of HD ric dimethyl arginine ( 1-ADMA) [24] . However, this remains a controversial subject, as it is not clear patients remain hypertensive despite the fact that 'dry weight' is reached [10, 11] . In addition, in several whether 1-ADMA levels are indeed significantly elevated in the dialysis population [25] . studies, no relation was observed between inter-dialytic weight gain and the inter-dialytic blood pressure rise Recent studies by Converse et al., have suggested an important role for the sympathetic system in the patho- [5, 6, 12, 13 ] .
From a haemodynamic point of view, volume over-genesis of hypertension in dialysis patients [26 ] . Using micro-electrodes to assess sympathetic nerve discharge, load only leads to an increase in blood pressure when the vascular tone does not adjust to the volume excess. they observed an increased sympathetic activity in haemodialysis patients (most of them being hypertensIn other words, for hypertension to occur, peripheral vascular resistance has to be increased. Indeed, diÂer-ive) in comparison with healthy subjects. This sympathetic overactivity appears to be related to the diseased ences in blood pressure in uraemic patients appear to be mainly determined by diÂerences in vascular resist-kidney, as in dialysis patients who had undergone bilateral nephrectomy, sympathetic nerve discharge ance [14] [15] [16] [17] . Whereas a local myogenic response (serving to autoregulate tissue blood flow) may contrib-equalled that of healthy controls. The mechanism behind the increased sympathetic nerve activity in ute to this increase in vascular resistance [18] , abundant evidence has emerged that also supports a role for dialysis patients remains as yet speculative. Possibly, uraemic toxins or ischaemic metabolites stimulate renal activated vasopressor systems in the pathogenesis of hypertension in HD patients. aÂerent nerves, either directly or via renal chemoreceptors, leading to an increase in sympathetic nerve activity through central nervous pathways [27 ] . Indeed, in
What is the role of pressor systems?
rats with experimentally induced renal failure, an increased turnover of norepinephrine was observed in In healthy subjects, the renin-angiotensin system is suppressed in response to volume loading. However, the locus coeruleus and posterior hypothalamic nuclei, which play an important role in the regulation of in uraemic patients, the renin-angiotensin system appears to be inappropriately activated in relation to sympathetic nerve activity [28] . All these data prompt further research towards the role of an increased the volume status, which may result in an inappropriate increase in systemic vascular resistance [14, 19] . sympathetic activity in the pathogenesis of hypertension in HD patients. For instance, it would be very Moreover, a correlation between blood pressure and plasma renin activity has been observed in patients interesting to investigate whether diÂerences in blood pressure between HD patients (at equal fluid status) with chronic renal failure [8 ] . Still, the renin-angiotensin system is not activated in all uraemic patients. In are related to diÂerences in sympathetic activity. a recent study investigating the relationship between volume loading and hypertension in haemodialysis How does haemodialysis treatment aÂect long-term patients, only three out of 10 patients responded with control of blood pressure?
an increase in blood pressure after interdialytic fluid loading. Renin and angiotensin levels decreased signi-An adequate blood pressure control with an incidence ficantly during the interdialytic fluid load. Interestingly, of hypertension below 5% was achieved by long treatthis decrease was less pronounced in volume responders ment time dialysis (three times a week for 8 h), as compared with volume non-responders [20] .
performed in the Tassin centre [29 ] . Blood pressure Recent evidence suggests an important role for the levels in these patients are even lower compared with endothelium in blood pressure regulation. Increased the healthy population [30 ]! Although these results levels of endothelium-derived vasopressor factors, like might suggest that volume overload is the only factor endothelin-1 are observed in HD patients, which might responsible for hypertension in dialysis patients, there be due to a decreased renal clearance or to endothelial are arguments that suggest that other factors play a cell damage. Endothelin-1 could increase blood pres-role. First, when the volume status of patients treated sure by augmenting peripheral vasoconstriction. in Tassin was compared with that of patients treated However, the role of endothelin-1 in the pathogenesis with shorter haemodialysis (three times a week for of hypertension in uraemic patients is still somewhat 4 h), only small and non-significant diÂerences in obscure, as endothelin levels were also found to be volume status (assessed by echocardiography, alfaincreased in normotensive HD patients [21 ] . Still, in ANP and echography of the inferior caval vein) were recent studies, an increase in endothelin-1 and a observed, whereas the incidence of hypertension was decrease in endothelium-dependent vasodilation was manyfold higher in the group treated with shorter observed after administration of erythropoietin, sug-dialysis. The main haemodynamic finding in the gesting a role for increased levels of endothelium-patients treated with long dialysis was a reduced peridependent vasoactive factors in the pathogenesis of pheral vascular resistance [30 ] . In a recent prospective study, the influence of both extra volume removal and rHuEPO-related hypertension [22, 23] . increase in dialysis time was studied independently. It contrast to a dihydropyridine calcium antagonist, the use of an ACE-inhibitor resulted in a significant appeared that both a decrease in dry weight without a change in dialysis time and an increase in dialysis time decrease in left ventricular dimensions [34] . Whether this will result in decreased cardiovascular morbidity without a change in dry weight, lead to a significant improvement in blood pressure control [31] . Could or mortality remains to be elucidated. When despite multi-drug antihypertensive therapy the patient still indeed an increased removal of uraemic toxins, implicated in sympathetic overactivity, play a role in the remains hypertensive, increasing dialysis time might be an option. blood pressure lowering eÂect of long dialysis? A role for middle molecules is suggested by the decreased
In conclusion, hypertension in the dialysis population is not a simple phenomenon, but has a complex incidence of hypertension with the use of haemofiltration, as found by Quellhorst et al. [32] . It certainly and intriguing pathophysiology. Further research should provide more insight into the complex role of appears worthwhile to address these important pathophysiologic questions in further research.
volume and vasopressor systems in the pathogenesis of hypertension in dialysis patients, and should address the role of blood pressure control in reduction of
Treatment of hypertension in HD patients
cardiovascular morbidity and mortality in dialysis patients. What should be our target blood pressure in the treatment of hypertension in dialysis patients? Until References now, this cannot be elucidated from present studies. However, it is probably advisable to be aggressive in 1 First, fluid and salt restriction is of utmost importance. [8] . The importance of the factor ( EGF ), insulin-like growth factor I (IGF-I ), and hepatocyte growth factor (HGF) are among the latter finding is unclear. Other actions of IGF-I that may contribute to improved outcome in rats with best-studied peptides. These growth factors participate in the cell transition into G 1 of the cell cycle. Growth-experimental ARF include the induction of EGFreceptors allowing for further augmentation of paracfactor-induced accelerated cell cycle transition of tubular cells during repair after acute injury is an important rine/autocrine actions of EGF [9] . IGF-I also activates inducible nitric oxide synthase (iNOS) generating function of these peptides. However, it is not the sole mechanism of function through which these peptides increased amounts of nitric oxide ( NO). Since iNOS isoenzyme is also expressed in proximal tubular cells contribute to accelerated recovery after acute ischaemic renal injury. Growth factors may also reduce the [10] , increased tubular NO activity may help to regulate mitosis, but its precise function is unclear. incidence of apoptosis of injured cells. Although apoptosis is commonly observed in the experimental Inhibitors of NOS reduce the IGF-I-accelerated rate of recovery from ARF in rats [11 ] . Whether this results settings of in vitro injury to cultured tubular cells or in vivo in rats with acute ischaemic tubular injury, its role from the reduction of IGF-I-induced microvascular or tubular NO activity or both is unknown. In any event, in human ARF is unclear. There may be several other metabolic actions of these growth factor peptides which these findings give rise to the possibility that the IGF-I-induced activation of iNOS contributes significantly contribute to repair of tissue integrity.
to the recovery from acute renal injury in the rat.
The role of EGF EÂects of IGF-I on catabolism and nephron haemodynamics
EGF and EGF receptors are normally expressed in TALH and distal tubules, but EGF receptors may also be present in the basolateral membrane of proximal In patients with chronic renal failure and in rats with acute renal failure rhIGF-I reduces muscle protein tubule cells. After ischaemic injury, distal tubular EGF expression and the urinary excretion of EGF decrease catabolism and promotes protein synthesis [5 ] . Since rats and patients with ARF are often severely catabolic, and both virtually disappear transiently, and EGF and its receptor become expressed in proximal tubules at this eÂect of rhIGF-I may also contribute to accelerated recovery. In addition, rhIGF-I has been shown sites of injury [1 ] . The decrease in distal tubular EGF expression is caused by disease events that interrupt to raise renal blood flow and GFR in normal rats and humans and in patients with chronic renal failure [7 ] . the function of an upstream region in the preproEGF gene promoter [2 ] .
The biological activities that may all contribute to mechanisms through which IGF-I accelerates the Exogenous administration of EGF in rats with nephrotoxic ARF accelerates the recovery of renal recovery from ischaemic ARF in the rat are summarized in Figure 1 . These multiple benefits suggest that function [3 ] . This report was the first demonstration of in vivo activity of a recombinant growth factor among diÂerent recombinant growth factors rhIGF-I may be particularly useful in the treatment of patients peptide to accelerate the recovery from ARF. This eÂect of EGF results, at least in part, from direct with ARF. mitogenic action of the peptide on proximal tubular cells as suggested by series of studies in cultured cells.
Lack of conclusive clinical evidence of a therapeutic role of rhIGF-I in acute renal failure The role of IGF-I To date two clinical trials have been performed to examine the eÃcacy of rhIGF-I to accelerate the IGF-I is more widely expressed along the nephron compared to other growth factor peptides. However, recovery from acute renal failure. In a single-centre trial, patients undergoing surgical repair of abdominal in normal rats and man IGF-I is not, or is only minimally, expressed in proximal tubules. In contrast, aortic aneurysms received rhIGF-I or placebo for 3 consecutive days [12 ] . Treatments were commenced IGF-I receptors are found abundantly in basolateral as well as apical membranes of proximal tubules. After shortly after conclusion of the surgical procedure.
Hence, at the time of initiation of therapy it was ischaemic ARF in the rat, IGF-I is transiently expressed in some proximal tubular cells and possibly unknown whether ARF was present in a given patient since serum creatinine may not have yet risen. In this by migrating macrophages suggesting a paracrine action of IGF-I in the natural repair after tubular study the incidence of ARF was remarkably low, the study was underpowered, and the eÂect of rhIGF-I on injury [4] . Several investigators have demonstrated that the exogenous administration of human recombin-the incidence or recovery of ARF could not be assessed.
However, there was a trend for rhIGF-I to improve ant (rh) IGF-I in rats with ischaemic ARF accelerates the recovery of renal function, the restoration of ana-GFR in these patients.
In another multicentre, placebo-controlled, randomtomic integrity and reduces mortality [5, 6 ] (for review see also [7 ] ). Cell culture studies suggest that IGF-I is ized clinical trial, 72 patients with established ARF Fig. 1 . Summary of biological activities of (endogenous or exogenous) IGF-I that may contribute to acceleration of recovery of renal function in animal models of ischaemic or tubulotoxic ARF.
secondary to transient shock, sepsis and other causes recovery of renal function than six injections of rhIGF-I given over a period of 3 consecutive days were treated with placebo or rhIGF-I, 100 mg subcutaneously twice daily, for up to 2 weeks. However, [16 ] . At present there is no data on the eÃcacy of HGF or any other growth factor peptide to reduce the rhIGF-I did not accelerate the recovery of renal function as measured by iothalamate clearance, creatinine incidence of delayed renal allograft function in patients. clearance or urine flow rate and there was no benefit in mortality rate in the rhIGF-I-treated subjects [13] .
Role of TGF-b
Thus, in contrast to many (but not all ) in vivo studies in laboratory animals, both clinical trials in humans thus far have failed to demonstrate that rhIGF-I EGF, IGF-I, and HGF (and possibly several other accelerates the recovery from ARF. This apparent growth-factor peptides) are transiently expressed or discrepancy may be explained by the underlying dis-overexpressed at sites of nephron injury in experimental eases causing ARF. In the rat models either transient or human ARF and seem to contribute to G 1 transition ischaemia or defined nephrotoxic events were used to and cell cycle progression resulting in mitogenic recovinduce limited and well defined renal injury. In con-ery of injured tubules. TGF-b 1 expression is also trast, in the multicentre clinical trial, most patients had increased in regenerating renal tubules in rats with severe underlying or associated diseases instead of a ischaemic ARF [17 ] . Since TGF-b 1 in many biological single transient event.
settings causes cell cycle arrest, its antimitogenic activity may help to oÂset the mitogenicity caused by several other factors and events. However, this is at
Role of HGF Key words: atrial natriuretic peptide; insulin-like in rats with ischaemic or toxic ARF [3] [4] [5] [6] [7] [8] [9] . The experigrowth factor I; clinical trials mental studies suggest that recombinant human IGF-I (rhIGF-I ) accelerates the recovery of renal function due to the renal haemodynamic eÂects, its mitogenic properties, other metabolic actions, and possibly due In acute renal failure (ARF ), proven therapies that to its eÂect of preventing apoptosis of tubular cells. have passed the test of rigorous state-of-the-art clinical Atrial natriuretic peptide (ANP) also has been demtrials are not available. Unfortunately, this list of failed onstrated to accelerate the recovery of renal function trials just has become longer. Recently, two clinical in rats with ARF. ANP appears to induce arteriolar trials examined the eÃcacy of insulin-like growth dilatation and reduce the rate of NaCl absorption factor I (IGF-I ) to improve outcome in patients with resulting in improved supply and reduced demand of ARF [1, 2] . One of these studies has been published in oxygen and substrate. Moreover, in a single centre, a full-length manuscript [2] , and data from the other open label clinical study, Rahman et al. had demontrial has been reported in abstract form [1] . Both strated that infusions of ANP raise the creatinine studies had been initiated following several years of clearance and reduce the need for haemodialysis in experimental research indicating that IGF-I accelerates patients with ARF [10] . the recovery of renal function and reduces mortality These results gave rise to the hypothesis that treatment with each of the two peptides would improve ANP in patients where ARF had been initiated scribing to the surgeons' skills, the incidence of severe ARF requiring renal replacement therapy was nil. independently.
A multicentre placebo-controlled, randomized A single centre clinical trial of rhIGF-I after renal clinical trial of rhIGF-I in ARF cross-clamping Recently, data from a multicentre, placebo-controlled Franklin et al. recently reported their findings in 54 clinical trial of rhIGF-I to improve outcome in patients patients who underwent surgery of the suprarenal aorta with ARF was published in abstract form [1] . Seventyor the renal arteries requiring periods of renal isch-two patients with ARF had been enrolled and were aemia of 60-70 min [2 ] , similar to the period of renal randomized to receive either rhIGF-I, 100 mg/kg, or ischaemia that is used in most experimental studies in placebo s.c. twice daily for up to 14 days. In this study, rats. In this study patients were randomized to receive treatments were initiated after ARF was established. either rhIGF-I, 100 mg/kg s.c., or placebo every 12 h Hence, the study evaluated whether the experimental for a total of 72 h beginning shortly after the surgery. treatment would accelerate recovery of renal function, Patients underwent measurements of the creatinine improve diuresis, reduce the need for renal replacement clearance before surgery and at 24, 48, and 72 h after therapy, or reduce mortality in patients with ARF the operation. None of the subjects developed severe rather than preventing ARF after potential injury. At ARF requiring dialysis therapy. The creatinine clear-a pre-determined interim analysis which included 72 ance tended to decline below baseline in the control subjects the study was terminated due to a lack of any group. In the rhIGF-I treated patients, the creatinine trend that would suggest that patients with ARF may clearance tended to increase, and was on average benefit from treatment with rhIGF-I ( Table 2 ).
7 ml/min greater than the pre-surgery values at 72 h ( Table 1 ). There was no diÂerence with regard to several other secondary outcome measures ( Table 1) . A multicentre, randomized, placebo-controlled trial The authors conclude that their 'findings establish the of a synthetic ANP derivative in ARF feasibility and potential utility for the use of IGF-I to reduce the incidence of postoperative renal dysfunction Allgren et al. studied the eÃcacy of a synthetic ANPderivative (Anaritide) in patients with ARF [11 ] . Fivein high risk patients' [2] .
This study, although well intended, failed to answer hundred-and four critically ill patients with ATN received either continuous i.v. infusions of anaritide, clinically important questions. This author is not sure what the possible benefit might be to reduce the 0.2 mg/kg/min, or placebo for 24 h. As primary outcome measurement, the investigators examined the incidence of transient 'renal dysfunction' when this is not associated with any improved clinical outcome. incidence of the dialysis-free survival rate at 21 days.
Secondary end-points included the need for renal Moreover, neither creatinine clearance nor serum creatinine concentrations were diÂerent at any given time replacement therapy, changes in serum creatinine, and mortality. Analyses were also performed in prospectduring the study or at hospital discharge. It would be diÃcult to justify the clinical use of an expensive ively-defined subgroups of patients with oligo-anuria versus normal or high urine output at baseline. There treatment based on this data. The study failed to examine the important question as to the eÃcacy of was no diÂerence in the primary outcome, the dialysisfree 21 day survival, between placebo and ANP-treated rhIGF-I to prevent the incidence or improve the outcome of ARF in high risk patients. Simply, the study subjects (Table 3 ). The subgroup analysis indicated that oliguric patients receiving ANP had a significantly was underpowered to answer this question, since sub- mortality, although the most convincing parameter, is unrealistic. ARF per se is not a lethal disease, at least improved dialysis-free survival rate (due to reduced in societies where continuous renal replacement therapneed for dialysis, not reduced mortality) compared to ies or haemodialysis are routinely applied. Mortality placebo treated oliguric patients. In contrast, in ARF-rates in severely ill patients with ARF have been patients with normal diuresis, ANP-treatment reported in the range of~25-85%. However, these worsened dialysis-free survival ( Table 3 ). There was data reflect the mortality due to underlying or associno benefit from ANP-treatment with regard to other ated severe diseases or multi-organ failure. In short, secondary outcome measures ( Table 3) .
patients die with but not of ARF. Hence, mortality is not a useful outcome parameter in therapeutic studies of ARF. Need for dialysis is also of questionable
What are reasonable conclusions?
clinical value. It suggests that renal replacement therapies are intrinsically bad compared to other therapies, which may or may not be true if examined by unbiased Unfortunately, these three recent studies of bioactive peptides in patients with ARF only add to the ( long) observers. A better outcome parameter for clinical trials in ARF might be the incidence of non-recovering list of disappointing clinical trials. RhIGF-I appears to have no benefit in severely ill patients with ARF, renal failure that requires chronic maintenance dialysis in surviving patients. In most settings, a large number and there may be a benefit of rather questionable clinical significance in patients with less severe renal of patients would have to be enrolled since only patients with long-term survival could be included in injury not requiring renal replacement therapy. The findings with Anaritide are even more puzzling. the analysis. The cost of such a trial might be prohibitive. Alternatively, to test the eÃcacy of an experimental Although a benefit was found in the subgroup of oliguric patients, it is disturbing to note that the therapy to improve the rate of recovery of renal function in ARF, only patients with ARF but without outcome was worse in subjects with normal diuresis. Although statisticians accept subgroup analyses as other severe associated diseases should be enrolled.
Clinical experience indicates that outcomes in this valid if they were prospectively defined, such analyses are always more likely to provide statistically positive group of patients is usually good and expensive drug therapy may not be necessary. results. This subgroup analysis demonstrated that a greater portion of oliguric patients receiving ANP did In summary, none of the three trials discussed above promotes enthusiasm for the use of rhIGF-I or not need dialysis therapy compared to placebo-treated individuals. This benefit may be of some clinical impor-Anaritide in patients with ARF in the clinical setting.
In this author's opinion all three studies show either tance assuming that renal replacement therapy is 
